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CHAPTER I 
INTRODUCTION 
In every living system, there must exist a means to 
convert energy taken in from food consumption to a form 
of energy that can be used by the organism. Some form 
of energy currency must be available in order for 
chemical reactions to be driven and in order for life 
processes to be carried out. Nature has provided a way 
for this enormous task to be accomplished by supplying 
this "currency" in the form of adenosine triphosphate 
CATP). In order to make ATP, a highly complex 
phosphorylation mechanism has evolved to convert 
adenosine diphosphate CADP) into ATP. 
A highly specialized organelle called the 
mitochondrion is now known to be responsible for the 
phosphorylation mechanism. Peter Mitchell's chemiosmotic 
hypothesis of ATP synthesis is now widely recognized as 
the mechanism by which phosphorylation takes place. The 
nature of this organelle is one of a highly membranous 
structure rich in proteins. The oxidative 
phosphorylation system is contained within the inner 
membrane of the mitochondria which is composed of 
approximately 70% protein and 30% lipid CHa~efi, 1985). 
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There is an abundance of literature on all aspects 
of oxidative phosphorylation and the nature of the 
organelle itself. As a result, there are many aspects 
of the mitochondria that have been elucidated. But at 
the same time, this large amount of research has 
generated controversy between researchers and has 
opened many new topics of discussion and research. One 
such area of research has been the use of inhibitors. 
Various compounds have been discovered that will block 
the flow of electrons in the respiratory chain Csee 
Hatefi 1985 for review). These inhibitors not only slow 
mitochondrial respiration but also act as a probe to 
allow researchers to functionally separate the 
respiratory complexes and study their function without 
interference from a neighboring complex. 
One class of compounds that has been shown to 
interfere with mitochondrial respiration are the 
tertiary amine local anesthetics and cardiac beta 
blockers. It is the purpose of this research to 
characterize the effects of these types of compounds on 
cytochrome oxidase. This research has four goals: 
1. To determine the inhibition of respiration in 
complex IV; 
2. To determine a site of action within the cytochrome 
oxidase; 
3. To determine the effect on the individual redox 
centers; 
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~. To determine the basis of the inhibition by 
observing changes in the following: 
a. Visible Spectra 
1. Cytochrome~ 
2. Cytochrome ~?. 
3.Copper associated with cytochrome ~ 
b. Enzyme Kinetics 
1. Km 
c. Oxidation/Reduction Potentials 
Since there are numerous drugs of these types, only 
three will be used in this study 1 dibucaine 1 tetracaine 1 
and propranolol. Their chemical structures are shown in 
Figure 1. These drugs were chosen because they each 
represent some structural similarities and structural 
differences; this is evident in that they each have ring 
structures and a long hydrocarbon chain containing a 
nitrogen atom. Tetracaine has a single ring whereas 
dibucaine and propranolol have two. Also, they vary in 
the degree of hydrophobicity, which, as will be pointed 
out later, is an important consideration in determining 
the degree to which they inhibit mitochondrial 
respiration. 
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Figure 1. Chemical structures of the local 
anesthetics dibucaine, tetracaine, and 
the cardiac beta-blocker propranolol. 
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CHAPTER II 
REVIEW OF LITERATURE 
The phosphorylation system in mitochondria is 
divided into five protein-lipid enzyme complexes. They 
are the following: 1. NADH: ubiquinone oxidoreductase 
(complex I); 2. succinate: ubiquinone oxidoreductase 
(complex II); 3. ubiquinol: ferricytochrome ~ 
oxidoreductase (complex III); ~. ferricytochrome ~: 
oxygen oxidoreductase (complex IV) S. ATP synthase 
(complex V). Functionally, complex Vis not a part of 
the electron transport chain, but interaction between 
the ATP synthase and the electron carriers is essential 
for the phosphorylation system to function properly. 
While all of the enzyme complexes are important and an 
intergal part of the phosphorylation procsss, it is 
complex IV that catalyzes the reduction of molecular 
oxygen to water and completes the electron transport 
process. 
Complex IV, or mare readily known as cytochrome 
oxidase, E.C. 1.9.3.1., catalyzes the ~-electron 
reduction of molecular oxygen by the donation of 
electrons from ferricytachrame ~· Cytochrome oxidase is 
composed of essentially two oxidation-reduction centers, 
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two heme centers known as cytochromes ~ and ~3, and 
their associated coppers, CuA and CuB CHatefi 1985). 
The enzyme complex spans the mitochondrial membrane 
completely CTzagoloff, 1982), allowing the enzyme to 
accept electrons from cytochrome ~ on the cytosol side 
and to reduce oxygen on the matrix side. 
Cytochrome ~ oxidase is an enzyme complex that has 
been the focus of numerous studies for over one hundred 
years. Although much has been learned, there is still 
much more to be elucidated about its structure and 
function. Cytochrome oxidase has a two fold function: 
first, the enzyme complex reduces molecular oxygen to 
water; second, in the reduction of molecular oxygen to 
water, protons are translocated across the inner 
membrane to create an electropotential gradient to 
provide free energy for the production of ATP. Many 
methods of study have been used to elucidate the 
function, structure, and mechanism of this complex 
enzyme system. I will summarize some of these methods 
and the information being obtained from them. 
The sequence of electron transfer in the mechanism 
of reduction of molecular oxygen to water has been the 
subject of much experimentation. Potentiometric as well 
as spectrophotometric techniques have been used to 
elucidate the mechanism CTzagoloff, 1982). Oxygen 
intermediates have also been studied at low temperatures 
by Chance and others CChance et. al, 197Sa,b,c; Lemberg 
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and Mansley, 1966; Wharton and Gibson, 1968). By using 
low temperature trapping techniques, the oxidase can be 
"trapped" into.various intermediate stages of oxidation. 
Use of multiple beam spectrophotometry permits the study 
of all the redox centers at the same time, allowing the 
sequence of electron transfer to be postulated by 
observing the time sequence of oxidation and reduction 
of the centers in question. These studies su~gest that a 
sequential mechanism is operating such that electrons 
flow sequentially from cytochrome ~ > CuA > ~3 CChance 
and Williams, 1955, 1956). Even with all of the work 
that has been done, the mechanism is poorly understood. 
A second important aspect of the function of 
cytochrome ~ oxidase is the translocation of protons 
across the membrane to form an electrochemical gradient 
used in the formation of ATP. The foundation of the 
chemiosmotic hypothesis proposed by Mitchell requires 
protons to be translocated across the mitochondrial 
membrane and is linked to the oxidation-reduction of the 
cytochromes that compose the electron transport chain 
(Mitchell, 1961). Three sites have been identified as 
being involved in the translacation of protons, one of 
which is cytochrome oxidase (Wikstrom et. al, 1981a,b). 
Potentiometric evidence suggests the location of these 
points. Electrons pass down the respiratory chain via an 
increased affinity for the redox componants of the chain 
for the electrons Cdue to an increasing electromotive 
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mid potential). The midpotential CLelative to the 
hydLogen couple) is used to measure the relative ease 
that a compound can either accept electrons or donate 
electrons. Compounds with a negative midpotential tend 
to donate electrons, therefore acting as reductants, 
while compounds with a positive midpotential accept 
electrons, therefore acting as an oxidant. By measuring 
the midpotentials of the cytochromes as described by 
Dutton and Wilson C197~), the ability of a cytochrome to 
reduce or oxidize a neighboring cytochrome can be 
determined. Potentiometric studies of electron transfer 
components can be used to elucidate aspects of electron 
transport mechanisms such as the determination of the 
sites of ADP phosphorylation in the chain. By measuring 
the potential difference between two neighboring 
cytochromes, one can then estimate if there is enough 
potential difference between the two centers for 
phosphorylation to take place. 7.3 kcal of standard free 
energy is needed to esterify the teLminal phosphate bond 
of ATP. Using the Nernst equation, this translates to 
roughly a 158 mV change in potential between redox 
components needed to produce this amount of free energy. 
Cytochrome oxidase Cbetween cytochLome ~ and oxygen) has 
a potential difference of 520 mV; this potential drop 
translates to a free energy change of -23.9 kcal, more 
than enough to phosphorylate ADP CTzagoloff, 1982). 
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A tremendous amount of investigation has focused 
on the mechanism of proton pumping associated with 
cytochrome oxidase Csee Wikstrom and Krab, 1979, 
Wikstrom and Krab, 1980, for reviews). Current views 
suggest that cytochrome a and its associated copper play 
an important role in the tranlocation of protons within 
this complex CWikstrom et. al, 1981a,b; Wikstrom and 
Krab, 1979; Wikstrom and Saari, 1977). It is suggested 
that cytochrome §.. and CuA act as a "gate" by which 
protons are shunted across the membrane, and the 
mechanism is most likely not a redox linkeq cycle as is 
the proton motive Q cycle in complex III CBoyer and 
Trumpower, 1981). Li et al., C1989), as well as Scholes 
and Malmstrom, Cl986), suggest that a conformational 
change in the protein is responsible for this "gating" 
effect. This change is postulated to be redox linked, 
thereby altering acid-base groups to account for the 
change in structure for proton translocation to occur. 
It is indicated that both cytochrome §.. and its 
associated copper CCuA) must be in the reduced form for 
the transition from the closed to open state to take 
place (Scholes amd Malmstrom, 1986), therefore resulting 
in a translocation of protons across the mitochondrial 
membrane. 
One of the greatest contributions to the 
understanding of the structure and function of 
cytochrome oxidase was· the development of the dual-
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wavelength spectrophotometer by Dr. Britton Chance as 
described previously (Chance, 1952c, 1951). Through a 
series of elegant spectrophotometric assays using the 
dual wavelength instrument, absorption bands were 
assigned to the many cytochromes in the electron 
transport chain including cytochrome ~ and cytochrome 
~3· Kellin and Hartree (1939), suggested that each 
cytochrome had a characteristic absorption band in the 
electromagnetic spectrum. An alpha band and a shorter 
wavelength Soret band were assigned by Kellin and 
Hartree as early as 193~ using a hand held spectroscope. 
They recognized that a cytochrome could be studied using 
the absorption bands for that particular heme. Dr. 
Chance's instrument, however, made it possible to 
measure a cytochrome even in a turbid sample (Chance, 
1952a). Much of what is known about the structure and 
function of cytochrome oxidase has been elucidated by 
Chance's methods. 
One important concept that was brought about by the 
use of dual wavelength spectroscopy was the study of 
crossover points in the respiratory chain. Chance and 
Williams, (1955 and 1956), defined the crossover point 
to be the site where a large difference in the reduction 
levels of neighboring carriers is observed. More 
succinctly, for a single phosphorylation step, the 
component involved will become oxidized. The net result 
being that the component on the oxygen side will become 
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more reduced while those on the substrate side more 
oxidized. If the reduction levels of the cytochromes are 
followed during steady state respiration Cafter the 
addition of ADP), the point at which the reduction 
changes to an oxidation is the crossover point CChance 
et al., 1955). Experiments were performed to determine 
the reduction levels of the various electron transport 
chain components including those of cytochrome oxidase. 
Not only was this method useful in determining crossover 
points, but also in determining the sequence of electron 
carriers. By measuring the absorbance change at the 
appropriate wavelengths in the presence of a reductant, 
which cytochromes were reduced at the same time another 
was oxidized could be made. Through these experiments, a 
good indication of the relative positions of the 
electron carriers was determined CChance and Hollunger, 
1961a,b,c,d,e,f). 
The use of compounds that inhibit electron 
transport at various sites has been applied using 
spectrophotometric methods to functionally isolate the 
various redox complexes. Use of the inhibitors not only 
defines the sequence of electron carriers, but also 
defines the location of the carrier in the membrane. 
Each complex of the electron transport chain has been 
found to be sensitive to one or more inhibitor compounds. 
Complex I is sensitive to rotenone, piericidin, 
and some barbiturates CPalmer, et. al, 1968). 
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Complex II is sensitive to 2-thenoyltriflouroacetone CTTFA). 
Complex III is inhibited by a number of compounds with one 
of the most potent being Antimycin A, an antibiotic from 
Streptomuces CSlater, 1973). Along with Antimycin A, a 
number of quinone analogs have been shown to inhibit 
this complex as well CYu et al. 1988). 5-n-undecyl-6-
hydoxy-~, 7-dioxobenzothiazole CUHDBT) CTrumpower, 1981), 
2-hydroxy-3-undecyl-1,~ napthoquinone CHUNQ) CHarmon and 
Struble, 1983), and BAL C2,3-dimercaptopropanol, 
CBritish anti-Lewsite), CGrigolova and Konstantinov, 
1977), have been shown to inhibit complex III. In 
addition, myxothiazole has been shown by Trumpower, 
C1981), to inhibit complex III as well. 
Cytochrome ~ oxidase is inhibited by a number of 
compounds as well. Carbon monoxide and cyanide have been 
shown to interact with cytochrome ~3, while azide has 
been shown to bind to cytochrome 2 1 thereby inhibiting 
the reduction of oxygen to water CTzagoloff, 1982). Of 
these inhibitors, carbon monoxide is of particular 
intrest in this research. Carbon monoxide will react 
with reduced cytochtome ~:s to form a carboxy-oxidase 
complex; cytochrome ~ can be subsequently oxidized while 
cytochrome ~~ remains reduced CTzaoloff and Wharton, 
1965). Spectral evidence for the carboxy-oxidase 
formation is seen by a 590 nm shoulder that appears 
adjacent to the 60~ nm cytochrome a band. Also, a ~30 nm 
band appears as well as a decrease in the ~~5 nm Soret 
band CChance, 1953a, Tzagoloff and Wharton, 1965). These 
spectral properties of carboxy-oxidase have been used 
extensively to determine the contributions of cytochrome 
~and ~~ to the alpha and Soret bands Csee Wikstrom et. 
al, 1976). 
The spectral properties of CuA are of interest to 
the current study in order to determine the oxidation-
reduction state of the copper atom. The reduced MINUS 
oxidized spectrum of CuA exhibits a trough instead of 
the characteristic peak that is seen in a reduced MINUS 
oxidized spectrum of an iron atom. The valence state of 
oxidized copper is +2. The paired electron valence state 
of the copper will absorb light in the near infra-red 
region of the electromagnetic spectrum. The absolute 
oxidized spectrum of CuA, therefore,has a peak at 830 
nm. The reduced form of CuA has a valence state of +1 
and is undetectable because of an unpaired electron 
spin, and the absolute reduced spectrum is indicated by 
a flat line. A reduced MINUS oxidized spectrum for CuA, 
then, is a trough, because a flat line subtracted from a 
peak produces a trough. 
Recent research has led to the discovery of a new 
class of inhibitors of cytochrome ~ oxidase. Local 
anesthetics and cardiac beta-blockers have been found to 
inhibit electron transport in cytochrome oxidase as well 
as alter same of the ion exchange mechanisms associated 
with the outer membrane. 
1~ 
Local anesthetics act reversibly to block the 
transmission of nerve impulses by decreasing the sodium 
conductance through the nerve membrane CCasonovas, 
1983). However, there is much debate as to the mechanism 
by which the local anesthetics black the sodium channel; 
some investigators have postulated that the molecule 
interacts with the lipid membrane that surrounds the 
protein CSeeman, 1972; Cerbon, 1972), while others have 
postulated that the protein itself is being altered 
(Richards et al., 1978). However, as pointed out by 
Gutierrez-Merino et al., C1989), Singer, C1980), and 
Chazotte and Vanderkooi, C1981), there is a strong 
correlation between anesthetic potency and the 
solubility of the anesthetic in the lipid bilayer Cwhich 
is related to the value of log P). Despite the studies 
that indicate that the protein is directly affected, the 
vast majority of the literature indicates that 
perturbation of the lipid membrane confers the change 
upon the protein instead of the protein being acted on 
directly. 
Dibucaine and tetracaine inhibit Ca2 + + Mg2 +-ATPase 
from skeletal mucsle sarcoplasmic reticulum. 
Calorimetric studies as well as f louresence measurments 
of sarcoplasmic reticulum membranes and determined that 
dibucaine and tetracaine shifted the ATPase to a more 
unstable conformation at concentrations close to those 
that inhibit the Ca2 +-Mg2 +-ATPase activity C~.o mM 
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tetracaine and 2.0 mM dibucaine) CGutierrez-Merino et 
al., 1989). Bradford and Marinetti, Cl981) have proposed 
that specific lipid-protein interactions play a role in 
sodium channel function and that local anesthetics can 
disrupt these interactions. According to Casanovas et 
al., Cl983), the lipid solubility of local anesthetics 
determines the amount of molecules that are able to 
cross the membrane; once inside the cell, the protonated 
hydrocarbon "tail" of the drug acts to block nerve 
conduction. The lipid solubilty of the drugs has also 
been correlated to their ability to inhibit the the 
protein calmodulin. Dibucaine, tetracaine, and lidacaine 
showed an affinity for this protein with a correlation 
to the octanal/water partion coefficient; namely, the 
mare hydrophobic the molecule, the higher the affinity 
far the protein CTanaka and Hidaka, 1981). 
Inhibition of electron transport in mitochondria by 
local anesthetics has been reported previously CChazatte 
and Vanderkooi, 1981). Chazotte and Vanderkooi reported 
that anesthetics of the alcohol and tertiary amine type 
inhibited electron transport in succinate oxidase, NADH 
axidase, NADH dehydrogenase, succinate dehydrogenase, 
and cytochrome ~ oxidase. A concentration dependence of 
the inhibition by the anesthetic was noted (Singer, 
1980; Vanderkooi and Chazotte, 1982; Chazotte and 
Vanderkooi, 1981). It was noted that the relative 
hydrophobicity of the molecule was related to the 
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potency of electron transport inhibition CSinger, 1980, 
1982; Casanovas, et al,. 1983), just as the 
hydrophobicity of the molecule contributes to their 
potency as anesthetics. These investigators suggested an 
interaction most likely with the lipid associated with 
the oxidase as described by Jost et al., C1973). 
Several investigators have used cytochrome oxidase 
as a model membrane protein to test the effects of 
various local anesthetics. Since much is known about the 
structure and function of cytochrome oxidase Cand that 
the oxidase requires lipids to make it functional CYu et 
al., 1975; Crane,· 1968), this protein, is an excellent 
model for the study of anesthetic interaction. Singer, 
C1980, 1982), and Casanovas et al., Cl983), report that 
the molecule can interact electrostatically with the 
oxidase, possibly competing for the charged cytochrome ~ 
binding site. Casanovas et al., C1983), characterized 
eight local anesthetics as being competitive, non-
competitive, or a mixed type inhibitor of cytochrome 
oxidase activity. Using isolated oxidase using 1~ Tween 
80 to reconstitute lipid depleted cytochrome oxidase, 
Chazotte and Vanderkooi C1981) and Vanderkooi and 
Chazotte C1982) demonstrated that the concentration of 
dibucaine needed to inhibit cytochrome oxidase in rat 
liver submitochondrial membranes was inversely related 
to temperature, further suggesting a hydrophobic 
interaction. They suggested a reversible perturbation of 
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protein conformation but could not determine if the 
anesthetics react with the protein directly Cas is the 
case of lipid-free isolated ATFase CAdade et al., 198~, 
1987; Chazotte et al., 1982; Vanderkooi and Adade, 
1986) or with its "boundary lipid" CJost et al., 1973). 
In addition to these studies, Singer C1983) has 
studied the effect of dibucaine, tetracaine, procaine, 
and benzacaine an the rate of electron transport of 
cytochrome axidase incorporated into proteolipasomes. In 
addition, the drugs effect upon hydrogen ion uptake in 
ionophore stimulated lipasames was investigated. 
Liposomes that are treated with 
trifluoromethoxycarbonylcyanide-phenylhydrozone CFCCF) 
and valinomycin plus K• cause the membrane to be 
permeable to hydrogen ions and thereby dissipate the pH 
gradient/electrical gradient resulting from the 
respiratory activity CHinkle et al., 1972). Singer found 
that in the presence of anesthetics, lipasames treated 
with an ionophare showed a much greater decrease in the 
turnover number as apposed to lipasomes that were 
untreated with an ianophore. Dibucaine, at a 
concentration of 2.5 mM, inhibited the enzyme turnover 
by 25%; but when the liposames were treated with an 
ionophore, the inhibition of enzyme activity by the drug 
increased to 75%. Singer postulates that a lipid site of 
action by the drugs could account for the decrease in 
turnover number. Studies by Singer using azide, a known 
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heme ligand CNicholls and Chance, 197~), does not change 
the degree of oxidase inhibition either in the presence 
or absence of an ionophore. Singer suggests that an 
interaction with the lipid boundry could account for 
these effects; also the relative potencies of the 
anesthetics studied follow their degree of 
hydrophobicity in the order dibucaine > tetracaine > 
benzocaine > procaine. Therefore, it could be· inferred 
that the site of action by the drugs is not directly 
affecting the heme, but the membrane associated with the 
protein. 
Propranolol is used to block beta-andergenic 
receptors; this results in a lowered heart rate, cardiac 
output, stroke volume, and oxygen uptake CLedingham and 
Lees, 1981). Propranolol inhibits respiration dependent 
ADP and Ca2 • uptake CKomai and Berkoff, 1979); Sobel et 
al., C1982), reported that it did not inhibit oxidative 
phosphorylation. Kamai and Berkoff C1979) found that O.~ 
mM propranolol inhibited uncoupler-stimulated 
respiration as well as calcium stimulated respiration in 
intact beef heart mitochondria. They also found that the 
affinity for propranolol was greatly lowered by adding 
SO mM KCl. At O.S mM propranolol, using malate-glutamate 
as substrate, state ~ respiration was measured to be 
O.l2 uatoms 02/min/mg and in the presence of SO mM KCl 
O.S mM propranolol, state ~ respiration increased to 
0.20 uatoms02/min/mg. They suggested that the charge 
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inteLaction between the KCL and pLOpLanolol pLevented 
the hydLophobic inteLaction needed between the dLug and 
the membLane. HeLdette, et al., Cl983) LepoLts a non-
specific inteLaction of pLopLanolol with dimyListoyl 
phosphatidyl choline CDMFC) bilayeLS. They also LepoLted 
that this dLug inhibits the calcium pump in saLcoplasmic 
Leticulum by paLtioning into the bulk lipid matLix. 
FuLtheL, pLopLanolol will bind to the mitochondLial 
membLane with a high affinity CHuunan-Seppala, 1972). 
Despite these extensive studies on the mechanism 
and type of inhibition that is seen by these dLugs, the 
site of action of these compounds in cytochLome oxidase 
has not been identified. 
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CHAPTER III 
MATERIALS AND METHODS 
All experiments utilized intact, coupled 
mitochondria that were isolated according to the method 
of Harmon and Crane, 187~. fresh beef hearts were 
obtained from a local slaughter house. All subsequent 
steps were performed on ice or in a cold room. Hearts 
were trimmed of all fat, valves, and pericardial 
membranes and ground in an industrial meat grinder. 
After grinding the heart, 1.5 times the volume of 
isolation medium containing 0.35 M sucrose, 0.5 M 
Na2PD3, 7.5mM MgCl2, and 1.0 mM succinate was added to 
the ground meat. The meat mixture was then separated 
into ~00 ml aliquots and homogenized with a Tekmar 
Tissuemizer blender on setting S for ~5 seconds. The 
homogenate was centrifuged in 1000 ml bottles at 500 x g 
in an International swinging bucket centrifuge for 20 
minutes. The supernatant was strained through ~ layers 
of cheese cloth Cthe pellet was discarded), and 
centrifuged at 26,500 x g for 15 minutes in a Sorvall 
RCS-B using a SA-600 rotor. The supernatant from this 
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step was discaLded. The mitochondLial pellet was 
Lesuspended in the initial isolation medium and 
homogenized using a size C FotteL-EvelhJem homogenizeL. 
The Lesuspended pellet was again centLifuged at 26,500 x 
g foL 15 minutes. The supeLnatant was discaLded and the 
pellet Lesuspended in a solution of 0.35 M sucLose, 7.5 
mM MgCl2, and 0.15 M KCl. The mitochondLia weLe washed 
twice with this solution and Lesuspended in a medium of 
0.35 M SUCLOSe and 7.5 mM MgCl2. The -mitochondLia WeLB 
suspended at a pLotein concentLation of appLoximately 
~0-50 mg/ml and stoLed fLozen at -~0° C in 1 ml 
aliquots. The pLotein concentLation was deteLmined by 
the BiuLet method descLibed by Yontani C1961). 
Oxygen Consumption Assays 
MeasuLement of oxygen consumption by the 
pola4og4aphic method descLibed p4eviously by Ha4mon and 
CLane, 1976, was used to deteLmine cytochLome oxidase 
activity as well as Km and Vm•H CHaLmon, 1988). Oxygen 
consumption was measu4ed with a ClaLk oxygen electLode 
in a glass, wateL-jacketed chambeL kept at a constant 
25° C. The following assay mixtuLe was added to the 1.7 
ml chambeL: 1.2 ml wateL, 0.3 ml sodium phosphate buffeL 
CpH 7.~. 80mM final concentLation), 100 ug mitochondLia, 
100 uM cytoch4ome ~ CSigma, Type VI). AscoLbate C 5.0 
mM final concentLation)and 12 ug N,N,N',N'-
tet4amethylphenylenediamine CTMFD) weLe added as 
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reductant. Protamine sulfate was used to inhibit the 
oxidase so an autoxidation rate could be measured. This 
value was then subtracted from the original value in 
order for a true measurement of cytochrome oxidase 
activity. 
Inhibition curves were generated by adding various 
amounts C0-10 mM final concentration) of either 
dibucaine, tetracaine, or propranolol to the assay 
mixture. The values of Km and Vm~x for cytochrome £ 
were obtained by varying the amount of cytochrome £ and 
adding the drugs at a concentration needed for 70% 
inhibition. The data was plotted using Eadie-Hofstee 
plots as describe by Ferguson-Miller et. al. C1976), and 
Segal, (1976) to determine the high and low affinity 
binding sites for cytochrome £· 
Log P values for the drugs were obtained from 
Cruickshank, Cl880), as determined using an 
octanol/water solvent system. The values reported for 
dibucaine, tetracaine, and propranolol are ~.~, 3.7, and 
3.9 respectively. 
Spectrophotometric Assays 
Dual wavelength kinetics using the ~~5 minus ~65 nm 
or 60~ minus 630 nm wavelength pair were recorded with a 
Johnson Research foundation CUniversity of Pennsylvania) 
DBS-3 scanning dual wavelength spectrophotometer. 
Spectra in the near infra-red region were recorded with 
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the same instuLment with a Kodak WLatten #15 filteL used 
as a second OLdeL filteL. SpectLa of caLbaxy-axidase 
weLe LecaLded using a VaLian DMS-1005 spectLaphatameteL 
modified ta function in a dual wavelength mode. 
Mitochondria were suspended at 2 mg protein/ml in 
0.25 M sucrose-SO mM sodium phosphate buffer CpH 7.~). 
3 ml of this suspension was added to a 3 ml cuvette and 
100 ug of cytochrome ~was added. Ascarbate CS mM final 
concentration) plus 12 ug TMPD was added as reductant. 
The absorbance change indicative of a reduction of 
cytochrome aa~~ was followed at either ~~5 nm minus ~65 
nm or 60~ nm minus 630 nm and measured on a strip chart 
recorder. Sodium dithionite was then added to ensure 
complete reduction of the sample. Where appropriate, 
the drugs were added before the reductant. 
Spectra of CuA were measured using the DBS-3 
instrument scanning from 700 nm to 900 nm using a 900 nm 
reference wavelength. Mitochondria were suspended at 6 
mg/ml protein in 0.25 M sucrose-SO mM sodium phosphate 
buffer CpH 7.~). Exogenous cytochrome~ ClOO ug) was 
added to a 3 ml sample and an oxidized spectrum was 
recorded. Ascorbate cs.a mM) plus 12 ug TMPD was added 
as reductant. A reduced minus oxidized spectrum was 
generated by subtracting the oxidized spectrum from the 
reduced spectrum. 
Carboxy-oxidase spectra were recorded using a 
Varian DMS-lOOS spectrophotometer modified to function 
in dual wavelength mode. The mitochondrial suspension 
was scanned from ~00 nm to 650 nm using a 630 nm 
reference wavelength. Mitochondria were suspended at a 
2 mg/ml protein concentration in 0.25 M sucrose-SO mM 
sodium phosphate buffer CpH 7.~); the 3 ml sample was 
reduced with 180 mM ascorbate, 5 ug TMPD, and 100 ug 
cytochrome ~· Carboxy-oxidase was generated by 
bubbling 100% carbon monoxide CCO) into the sample for 5 
minutes. Where appropriate, the drugs were added before 
reduction with ascorbate, TMPD, and cytochrome ~· Drugs 
were present at concentrations needed for 70% inhibition 
of mitochondrial respiration as determined 
polarographically in all assays where drugs were used. 
The oxidation-reduction potentials of cytochrome 
oxidase were measured with a platinum-calomel electrode 
pair as described by Dutton and Wilson C197~) using the 
DBS-3 dual wavelength instrument as described previously 
CHarmon and Basile, 198~). Mitochondria were suspended 
at a concentration of 2 mg/ml in 0.25 M sucrose- 50 mM 
Na2P04 buffer pH 7.~ that had been bubbled with nitrogen 
to exclude oxygen. The mitochondrial suspension ClOml) 
was introduced into a "Dutton" cuvette. The cuvette is 
designed to allow the electrodes to be immersed into the 
solution to facilitate potential measurment. Side arms 
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present on the cuvette allow addition of reductant or 
oxidant. 
Cytochrome ~ ClOO ug) was added to the 10 ml of 
mitochondrial sample. 2,3,5,6-tetramethyl-p-phenylene 
diamine COAD, 60 uM), 156 uM phenazine methosulfate 
CPMS), and 3 uM duroquinone (final concentrations) were 
used as voltage Cpotential) mediators (Dutton and 
Wilson, 197~). Where used, drugs were present at 
concentrations needed for 70% inhibition. The potential 
of the solution was varied by addition of ferricyanide 
and/or dithionite solutions. The potential was set at -
300 mV with dithionite, and a reduced spectra was 
recorded from 530 nm to 630 nm .using a 630 nm reference 
wavelength. The sample was subsequently oxidized by 
step-wise addition of ferricyanide. A spectrum was 
recorded for approximately every 5 mV change in 
potential resulting in an oxidized minus reduced 
spectra. Midpotentials were calculated by measuring the 
extent of oxidation of the sample as compared to a final 
oxidation by setting the potential to +~00 mV. 
Potentials for each subsequent oxidation were plotted 
against the log of the ratio of oxidized and reduced 
portion of the sample. 
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CHAPTER IV 
RESULTS 
The inhibition of ascorbate plus TMPD driven 
cytochrome oxidase activity in intact beef heart 
mitochondria is dependent on the concentration of drug 
present (figure 2). In the presence of dibucaine, 50% 
inhibition is observed at a concentration of 1.1 mM with 
over 90% inhibition obtained at a concentration of 2 mM 
dibucaine. Propranolol is slightly less toxic in that 
the concentration needed for 50% inhibition is 2.0 mM. 
Tetracaine is the least toxic to ascorbate plus TMPD 
driven cytochrome oxidase respiration requiring a 
concentration of 5 mM for 50% inhibition. Figure 3 
demonstrates that the concentration dependence is 
directly related to the log of the octanol/water 
partition coefficient Clog P). If the concentration of 
drug ls plotted versus log P, a linear relationship is 
evidenced as was reported by Chazotte, et. al., C1981). 
The enzyme kinetics for cytochrome oxidase activity 
are altered by these drugs. The Km and Vm~M using 
cytochrome ~ as a substrate for the oxidase were 
measured. Table I displays the values for Km and Vm•H 
for cytochrome ~ for the control as well as in the 
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figure 2. Inhibition of mitochondrial respiration 
by dibucaine, tetracaine, and propranolol 
plotting percent inhibition vs. 
concentration. A 50% inhibition 
occurs at a concentration of 1.1 mM for 
dibucaine, 1.2 mM for propranolol, and 
5.0 mM far tetracaine. 
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presence of dibucaine, tetracaine, and propranolol. 
When drugs were used, concentrations of 1.5 mM 
dibucaine, 2.0 mM propranolol, and 5.0 mM tetracaine 
were added to the assay, the concentrations needed for 
70% inhibition of cytochrome oxidase respiration. 
Figures ~. 5, 6, and 7 are the Eadie-Hoffstee plots for 
the control and the experiments with the drugs present. 
The high and low affinity binding sites are clearly 
visible as two distinct lines with separate Km's and 
Addition of ascorbate plus TMPD to mitochondria in 
the presence or absence of dibucaine, tetracaine, or 
propranolol results in approximately 90% reduction of 
cytochrome ~ oxidase Ccompared to dithionite reduced 
sample) as measured by the absorbance increase at 60~-
630 nm as seen in Figure 8. In contrast, only 50% 
reduction of the oxidase is observed at ~~5-~65 nm when 
ascorbate plus TMPD are used as a reductant when the 
drugs are present at a concentration needed for 70% 
inhibition CFigure 9). 
As shown in Figure .10, reduced cytochrome oxidase 
exhibits the characteristic alpha band at 60~ nm; 
addition of CO results in an increase in 590 nm 
absorbance as well as the appearance of a ~30 nm band 
due to the formation of ferrous carboxy-cytochrome ~3· 
In the presence of 1.5 mM dibucaine, the alpha band at 
60~ nm is still observed using ascorbate plus TMPD as 
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1.5 mM 
5.0 mM 
2 .0 mt1 
TABLE I 
SUMMARY FOR Km AND Vmax FOR CYTOCHROME OXIDASE 
Drug High Affinity Low Affinity 
Km Vmax Km Vmax 
Cum) Cnm 02/min/m9,) Cum) Cnm 02/min/mg) 
None 0.6 95.56 23.Lf 389.6 
Dibucaine 29.Lf 288.73 201.f.0 882-.31.f 
Tetracaine 8.71 138.02 26 .. 28 911.Slf 
Propranolol 21.5 2lf5.09 lf2.19 '189.12 
w 
w 
Figure ~. Eadie-Hoffstee plot of cytochrome 
oxidase activity using cytochrome £ 
as substrate. Assay contained the 
following: 1.2 ml water, 0.3 ml 
Na2PD4 buffer CpH 7.~), 100 ug 
mitochondria C2mg/ml protein), 100 
ug ascorbate plus 5 ug TMPD as 
reductant. Cytochrome £ CSigma type 
VI) was varied from 0.5 uM to 100 
uM. 
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Figure 5. Eadie-Hoffstee plot of cytochrome 
oxidase kinetics using cytochrome ~ 
as substrate in the presence of 1.5 mM 
dibucaine. Conditions are as described 
in Figure ~. 
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figure 8. Reduction of cytochrome oxidase as 
measured using the 60~ minus 630 nm 
wavelength pair. Cytochrome ~depleted 
mitochondria were suspended at 2 mg/ml 
in sucrose-SO mM sodium phosphate buffer 
CpH 7.~). 5 mM ascorbate and 12 ug 
TMPD with 200 ug cyt. ~were used as 
reductants. 
Drugs were present where indicated at 
1.5 mM dibucaine, 5.0 mM tetracaine, 
and 2.0 mM propranolol. 
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Figure S. Reduction of cytochrome oxidase as 
measured using the ~~5 minus ~65 nm 
wavelength pair in the presence of 
either 1.5 mM dibucaine, 2.0 mM 
propranolol, or 5.0 mM tetracaine. 
Conditions as described in 
Figure 8. 
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Figure 13. Effect of 2.0 mM propranolol on the 
formation of carboxy-oxidase. Trace 1, 
reduced MINUS oxidized in the presence of 
propranolol. Trac 2, same as trace 1 except 
100% CO was bubbled into the sample. 
Conditions are as described in Figure 
8. 
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Figure 11. Effect of 1.5 mM dibucaine on spectrum of 
carboxy-ferrous cytochrome oxidase. 
Samples prepared as desribed in figure 8. 
Trace A: reduced minus oxidized 
difference spectrum in the presence of 
dibucaine. Trace 2: same as trace 1 
except 100% CO was bubbled into the 
sample for 5 minutes. Conditions are 
as described in Figure 8. 
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Figure 12. Effect of 5.0 mM tetracaine on the 
formation of carboxy-oxidase. Trace 
l:reduced MINUS oxidized spectra in the 
presence of tetracaine. Trace 2, same 
as trace 1 except 100% CO ~as bubbled 
into the sample. Sample prepared as in 
Figure 8. 
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Figure 10. Spectra of carboxy-ferrous cytochrome 
oxidase in intact mitochondria. Samples 
were prepared as described in Figure 8. 
Trace 1: reduced minus oxidized. 
Trace 2: same as trace 1 with 100~ CO 
bubbled into the sample for 5 
minutes. Conditions are as described 
in Figure 8. 
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reductant, but the absorbance increase at 590 nm is not 
observed CFigure 11). This is to be expected since the 
kinetic date Y:Y:5-Y:65 nm shows the dibucaine prevents the 
reduction of cytochrome ~3, which is necessary for the 
formation of carboxy-oxidase. Tetracaine at a 
concentration of 5.0 mM and propranolol at a 
concentration of 2.0 mM also prevents the formation of 
carboxy-oxidase as shown in Figures 12· and 13. In all 
cases, the drugs inhibit the reduction of cytach~ome a~. 
Not only is the ·sso nm band not present~ but there is 
the absence of the Y:30 nm band that is also due to 
ferrous carboxy-oxidase CChance, 1S53a). 
The presence of dibucain~, tetracaine, and 
propranolol alters the.midpotential of cytochrome~ 
oxidase. Figure lY: displays a typical oxidation-
reduction titration of cytochrome oxidase as measured at 
60Y:-630.nm. figures 15, 16, and 17 show the redox 
titration for dibucaine, tetracaine, and propranolol. 
The midpotential is the potential at which the log of 
the ratio of oxidized-reduced is a value of 0, or when 
exactly half of the o~idase aample is reduced and half 
is oxidized. The midpotentials for the control and 
oxidase treated with 1.5 mM dlbucaine, 5.0 mM 
tetracaine, and 2.0 mM propranolol are shown in Table 
II. Tetracaine alters the shape of the redox titration 
curve much more than does either dibucaine or 
propranolol. There appears to be two different mid-
SY: 
TABLE II 
SUMMARY FOR MID PdTENTIALS FD~ CYTOCHROME OXIDASE 
Drug 
None 
Dibu.caine 
.Cl .5 mfi) 
Tetracaine 
(5.0 mM) 
Propranolol 
C2.0 mM) 
Mid Potential 
2'13 mV 
255 mV 
350 mV 270 mV 
265 mV 
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Figure 1~. Oxidation-reduction titration far 
cytochrome axidase as measured using 
the 60~ nm band. Mitochondria were 
suspended at 2 mg/ml protein in 0.25 M 
sucrose-SO mM Na2P04 buffer CpH 7.~). 
Cytochrome ~ was present at a 
concentration of 100 ug. Redax 
mediators used were the fallowing: 
60 um 2,3,5,6-tetramethyl-p-phenylene 
diamine CDAD), 156 uM phenazine 
methasulfate CPMS), and 3 uM 
duroqinane. Mitochondria were kept 
under an atmosphere of argon. 
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Figure 15. Oxidation-reduction titration for 
cytochrome oxidase in the presence of 
1.5 mM dibucaine. Conditions are as 
described in Figure 1~. 
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Figure 16. Oxidation-reduction titration for 
cytochrome oxidase in the presence of 
5.0 mM tetracaine. Conditions are as 
described in Figure 1~. 
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FiguLe 17. Oxidation-Leduction titLation foL 
cytochLome oxidase in the pLesence 
of 2.0 mM pLOpLanolol. Conditions aLe 
as descLibed in FiguLe 1~. 
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potentials, one at 2~5 mV and one at 385 mV. These 
values correspond ta the midpatentials far cytochrome ~ 
and cytochrome ·~3, respectively, as reported by 
Wikstrom, et al., Cl976). This observation will be 
examined further in the Discussion section. As 
demonstrated in Figure 18, ascarbate plus TMPD is 
capable of reducing the "visible" CuA moiety in the 
absence but not in the presence of 1.5 mM dibucaine. 
Reduction of the CuA center is shown by a decrease in 
the absarbance in the 8~0-860 nm region of a reduced 
minus oxidized spectrum (Griffith and Wharton, 1961; 
Wharton and Tzagalaff, 196~). In the presence of 
dibucaine, addition of dithianite causes a decrease in 
the near infra-red absarbance indicating that the CuA 
center is capable of being reduced by a strong 
reductant. Similar results are obtained using 
mitochondria washed with bathaphenanthraline sulfate ta 
remove adventitious copper CGriffith and Wharton, 1961; 
Beinert, et. al., 1970; Harman and Crane, 197~b). 
Therefore, the copper signal indicated in Figure 18 is 
not due to adventitious copper, but the copper 
associated with cytochrome~ CCuA). 
Figure 18. Spectra of CuA in intact beef heart 
mitochondria. Mitochondria were 
suspended at 6 mg/ml protein in 0.25 M 
sucrose-SO mM Na2P04 buffer CpH 7.~). 
A Kodak # 15 filter was used as a 
second order filter. The sample was 
reduced using 100 ug cytochrome ~, 5.0 
mM ascorbate and 12 ug TMPD. Where 
appropriate, dibucaine was present at 
a concentration of 1.5 mM. 
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CHAPTER V 
DISCUSSION 
This study has examined the effects of three local 
anesthetics and a cardiac beta-blacker, prapranolal, an 
cytochrome c axidase respiration as well as the effects 
on the individual redox centers cytochrome ~. CuA, and 
cytochrome ~3· Unlike previous studies CChazotte and 
Vanderkooi, 1981; Singer, 1983; & Singer, 1980) that 
only characterized the effects of the drugs on electron 
transport activity this investigation sought to 
elucidate an exact site of inhibition by these compounds 
within the oxidase. Chazotte and Vanderkooi C1981) 
investigated the effects of local anesthetics on the 
entire mitochondrial electron transport chain utilizing 
many of the partial reactions to isolate each complex 
CHatefi, 1985). These investigators reported LD-50 
values for dibucaine of 9 mM and tetracaine of 25 mM for 
cytochrome axidase activities. According to Harmon 
(unpublished results), 50% inhibition ~f succinate 
oxidase activity is observed in the presence of 1.25 mM 
dibucaine in intact mitochondria and at 9 mM dibucaine 
concentration in 9~% inverted submitachondrial 
particles. The concentration dependence of the 
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inhibition by the local anesthetics is dependent upon 
the orientation of the membrane vesicles used and 
indicates that the inhibitory site is present on the C-
side of the membrarte and not on the M-side. That the 
the sites of action of the anesthetics are on the C-side 
of the membrane would explain why Chazzotte and 
Vanderkooi's 50% inhibition values were an order of 
magnitude higher than the ones report'ed in this current 
study CChazotte and Vanderkooi used submitochondrial 
particles). 
Kinetic parameters of cytochrome ~ oxidase were 
also investigated; dibucaine, tetracaine, and 
propranolol all exhibited a mixed-type inhibition. That 
is, both Km and Vm•x are altered by the drugs. Singer 
C1980) reported the same results using the local 
anesthetics dibucaine, tetracaine, and procaine. He 
postulates that the charged end of the anesthetics 
competes with substrate for binding while the non-polar 
end interacts with oxidase-associated phospholipids to 
produce non-productive complexes. This conclusion seems 
logical in light of supporting the assumption that these 
drugs interact with the lipid bilayer CCasanovas, et. 
al, 1983; Kamai & Berkoff, 1883); Singer, 1983; 
Gutierrez-Merino, et. al, 1989). However, the data in 
the current study as well a~ data bf Singer Cl980) 
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indicates that the more hydrophobic the drug molecule, 
the lower the affinity of cytochrome oxidase for 
cytochrome ~. thus resulting in an elevated Km and VmaM . 
Each of the molecules studied, dibucaine, 
teteracaine,, and propranolol, have structural 
similarities in that they each have a hydrophobic head 
group and a long hydrocarbon tail containing a tertiary 
amine. It is feasible that the head group dictates the 
relative hydrophobicity of the drug and determin~s to a 
great extent the log P of the mbl~cule. Therefore, the 
head group could dictate the ease by which the molecule 
may cross the mitochondrial membrane. Once penet~ating 
the membrane, the amine group, Which would bear a 
positive charge at physiological pH, could be 
responsible far the competition for the charged 
cytochrome ~binding site. The disruption of the lipid 
bilayer by the hydrophobic end of the molecule could be 
responsible far a canformatian~l change to the oxidase 
resulting in the mixed-type inhibition. If the drugs 
competed only for the charged cytochrome ~ binding site, 
then a strictly competitive inhibition would be 
displayed. 
An aspect of the inhibition of cytochrome oxidase 
by these compounds not readily apparent to previous 
investigators are the effects upon the oxidation and 
reduction levels between the redox centers, cytochrome 
~. CuA, and cytochrome ~3· Using the dual wavelength 
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spectrophotometric methods developed by Chance C1952c, 
1951, 1961; Chance & Hallinger, 1961a, 1961b, 1961c), 
oxidation-reduction levels between the redax centers 
could be resolved. The "neoclassical" model far 
cytochrome oxidase holds that approximately 80-90% of 
the absorbance of reduced oxidase at 60~ nm is due to 
ferrous cytochrome ~. the 'remainder due to ferrous 
cytochrome ~3; both cytochromes absorb light equally at 
~~5 nm (Wikstrom, et. al., 1976). The data in Figures 8 
and 9 are consistent with this model. In the presence 
of dibucaine, tet~acaine, or propranolol, over 80% of 
the 60~ nm and approximately 50% of the ~~5 nm 
absorbance is recorded when reduced with ascorbate plus 
TMPD. Thus, these thr~e drugs inhibit electron 
transport between cytochrome §.. and §..:;!!:, allowing the 
reduction of cytochrome ~ C80% of 60~ nm at 50% of ~~5 
nm absorbance) but not cytochrome ~3· 
The neoclassi.cal 50/50 hypothesis, as reviewed by 
Wikstrom et al., Cl976), relies upon the formation of a 
mixed valence cytochrome oxidase consisting of a ferric 
cytochrome §.. and a fe!"'.rous cytochrome ~"3 • C~t:•:+ ~"3::.;?+). 
"Mixed valence" oxidase can be made using· several 
methods CGreenwood, et. al., 197~) the simplest method 
being to reduce the oxidase with a reductant such as 
dithionite, bubbling the sampl~ with carbon monoxide, 
and subsequently oxidizing cytochrome §..with 
ferricyanide. The carbon monoxide binds cytochrome ~3 
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"trapping" it in the reduced form, while C!Jtochrome §. is 
free to be oxidized. B!d using this form of the oxidase, 
absorbance bands ma!d be assigned to C!Jtochrome §. or §_3 
and also the relative contributions to the size of the 
band in question CWikstrom, et al.,1976). Ferrous 
carbox!J-oxidase has a ver!d distinct spectrum; not onl!d 
is the alpha band at 60~ nm present due to reduced 
C!Jtochrome §., but also a 590 nm shoulder appears. This 
shoulder at 590 nm is due the 20% of the 60~ nm that is 
due to C!Jtochrome §.::!: caused b!d the ligand of carbon 
monoxide bound to this C!Jtochrome. In addition, the 
appearance of a ~30 nm band due to the formation of 
carbox!d oxidase is seen CChance, 1953a). In the current 
stud!J, the bands were used extensivel!d to provide 
information concerning the site of inhibition of the 
drugs in the oxidase. The data obtained from absorbance 
measurments at the 60~-630 nm and ~~5-~65 nm wavelength 
pairs suggested that C!Jtochrome §. is reduced while 
C!Jtochrome §.::!!! is oxidized in the presence of the drugs. 
The carbox!J-oxidase spectra validated this finding. 
B!d using the anesthetics or the propranolol, a 
"reverse" mixed-valence oxidase can be made. Spectra in 
Figures 10 and 11 demonstrate that C!Jtochrome a is 
reduced due to the fact the 60~ nm peak is present, but 
the 590 nm and ~30 nm peaks are much smaller or not seen 
at all. That there is a small ~30 nm band and a small 
590 nm band when the drugs are present needs to be 
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addressed. First, the drug concentrations used were 
only at a concentration needed to inhibit the oxidase 
70%, therefore, a small amount of the oxidase is not 
inhibited and ~~ is able to bind carbon monoxide because 
it is reduced. A second possibility is that other 
cytochromes, namely cytochrome ~. could be sufficiently 
perturbed by the drugs as to bind CO and cause a small 
~30 nm peak to be seen. As can be clearly seen in the 
figure, the spectrum for cytochrome ~ is altered to a 
great extent. The implications of this data are twofold; 
first, the data demonstrates that the drugs inhibit the 
flow of electrons between cytochrome~ and~~. second, 
it is possible to form a "reverse" mixed-valence oxidase 
using an inhibitor not currently known to be a ligand of 
either cytochrome. 
Oxidation-reduction titrations were carried out 
using the band at 60~ nm that has been assigned to 
cytochrome a CKielin and Hartree, 1939; Wikstrom et al., 
1976). The data shows that dibucaine and propranolol do 
not alter the midpatential of the oxidase ta any great 
degree. However, the Nernst plat in the presence of 
tetracaine indicates two distint mid potentials, one 
midpatential is apparent at a value of 270 mV and a 
second with a midpatential at a value of 365 mV. These 
numbers correspond well with the potential reported ta 
be that of cytochrome ~ and ~:" respectively (Wikstrom et 
al., 1976). A possible explanation of the split that is 
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observed in the presence of tetracaine is that the 
molecule inserts itself into the bilayer Car perhaps 
into the protein itself) thereby interfering with the 
heme-heme interaction as described by Leigh, et al., C197~). 
Separation of the midpotentials could be related to the 
structure of the tetracaine in that this molecule is the 
smallest of the drugs studied. The tetracaine might 
have the ability to insert itself around the heme and 
cause a steric effect not possible with a larger 
molecule such as dibucaine or propranolol. 
The potentials for cytochrome oxidase are based on 
the state of the enzyme, that is, energized oxidase 
using ATP, aerobic oxidase, and anaerobic oxidase have 
been demonstrated to have different mid potentials. 
Malmstrom C1973) has demonstrated that heme-heme 
interaction could cause the midpotentials to shift. 
This heme-heme interaction is not of the type in which 
there is a direct dipole-dipole interaction between the 
iron atoms, but a much more subtle interaction CWilson 
and Leigh, 1972; Leigh et al., 197~). It is suggested 
by Leigh and coworkers (1972, 197~) that both hemes are 
in electropotential equillibrium with each other and 
that when one cytochrome is reduced, the potential of 
the other shifts to a higher potential via a heme-heme 
interaction. This interaction is postulated to be the 
reason why two distinct high and low potentials can be 
resolved using the 60~ nm band that is due to 80% 
cytochrome~' the law potential heme CWikstram et al., 
1976; Malmstram, 1973). 
The data obtained far the copper associated with 
cytochrome a indicates that CuA is not reduced in the 
presence of the drug dibucaine. This, along with the 
other data in this study, indicates that dibucaine 
blacks electron transport between cytochrome ~and CuA. 
The data that has been collected in this study 
indicate that these drugs do in fact inhibit cytochrome 
axidase respiration in intact mitochondria; moreover, 
the data suggests that the site of inhibition is between 
cytochrome ~and CuA. Harman (unpublished data) has 
shown that carbon monoxide recombination is not effected 
in the presence of these compounds. Flash photolysis 
experiments as described previously CHarman and 
Sharrock, 1982) have shown that CO recombination is not 
affected with respect to.either the energy of activation 
or the occupancy of the CO molecules. While these drugs 
do prevent cytochrome ~~ reduction, once reduced, 
cytochrome ~3 behaves in a normal manner with respect to 
its ability ta bind carbon monoxide. This data suggests 
that the drugs do not alter cytochrome ~::i:. 
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CHAPTER VI 
CONCLUSIONS 
This study did not try to elucidate the mechanism 
of anesthesia and their action as antiarr~thmic drugs. 
The site of inhibition was found to be between 
cytochrome £ and CuA, and all three drugs, tetracaine, 
dibucaine, and propranolol, have the same apparent site 
of action within the oxidase differing only in the 
concentration needed to inhibit respiration. 
The ramifications of this· research are two fold; 
one, the sites of inhibition by the drugs were 
dtermined. Two, the data indicates that the drugs could 
be a useful tool to study the structure and function of 
cytochrome oxidase mare fully. Three areas of research 
could benifit by the use of these compounds. The first 
area is in the study of the midpotentials of cytochrome 
£and £3 in the presence of these drugs. This research 
only looked at the effect of the drugs on the mid-
potential as measured at 60~-630 nm using the same 
mediators and the same oxidants and reductants. The 
patentiometric data indicates that these drugs 
(especially tetracaine) could be used to further study 
the interaction of midpotentials between cytochrome £ 
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and cytochrome ~3· Secondly, proton pumping experiments 
could be very productive in so far as information that 
could be gained about the mechanism in cytochrome 
oxidase. The drugs allow cytochrome ~to be reduced 
while CuA is oxidized. The proposal of Wikstrom and 
Sarri C1977) and Li et al. C1988) Cthat in order for the 
oxidase to pump protons cytochrome ~ and CuA must both 
be reduced) could be further investigated. 
Thirdly, the use of the drugs in the study of 
oxygen intermediates at low temperatures might also 
prove interesting. The reverse mixed-valence oxidase 
that is formed in the presence of the drugs could used 
to further understand the mechanism of oxygen reduction 
and the sequence of electron transfer between the 
centers and to molecular oxygen. 
By further experimentation, these drugs, which have 
the ability ta functionally separate cytochrome ~and 
cytochrome ~3, could prove ta be instrumental in our 
understanding of cytochrome oxidase. 
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